{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:17:30Z","timestamp":1788585450886,"version":"build-2803163510"},"reference-count":47,"publisher":"Japan Atherosclerosis Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.5551\/jat.rv22052","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:09:33Z","timestamp":1779919773000},"page":"1111-1123","source":"Crossref","is-referenced-by-count":2,"title":["Current and Future Perspectives of LDL-C Lowering Therapies 2026"],"prefix":"10.5551","volume":"33","author":[{"given":"Hayato","family":"Tada","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Usui","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Bor\u00e9n J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokg\u00f6zoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J, 2017; 38: 2459-2472","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Cholesterol Treatment Trialists\u2019 (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA\/ACC Guideline on the Management of Blood Cholesterol. Circulation, 2019; 139: e1082\u2011e1143","DOI":"10.1161\/CIR.0000000000000624"},{"key":"4","unstructured":"4) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J, 2020; 41: 111\u2011188"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. J Am Coll Cardiol, 2020; 75: 2553-2566","DOI":"10.1016\/j.jacc.2020.03.057"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Harada-Shiba M, Arai H, Ohmura H, Okazaki H, Sugiyama D, Tada H, Dobashi K, Matsuki K, Minamino T, Yamashita S, Yokote K. Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022. J Atheroscler Thromb, 2023; 30: 558-586","DOI":"10.5551\/jat.CR005"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Harada-Shiba M, Ohtake A, Sugiyama D, Tada H, Dobashi K, Matsuki K, Minamino T, Yamashita S, Yamamoto Y. Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. J Atheroscler Thromb, 2023; 30: 531-557","DOI":"10.5551\/jat.CR006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Tada H, Kaneko H, Suzuki Y, Okada A, Takeda N, Fujiu K, Morita H, Ako J, Node K, Takeji Y, Takamura M, Yasunaga H, Komuro I. Familial hypercholesterolemia is related to cardiovascular disease, heart failure and atrial fibrillation. Results from a population-based study. Eur J Clin Invest, 2024; 54: e14119","DOI":"10.1111\/eci.14119"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Tada H, Nohara A, Inazu A, Sakuma N, Mabuchi H, Kawashiri MA. Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. J Atheroscler Thromb, 2018; 25: 783-789","DOI":"10.5551\/jat.RV17024"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Tada H, Kojima N, Takamura M, Kawashiri MA. Sitosterolemia. Adv Clin Chem, 2022; 110: 145-169","DOI":"10.1016\/bs.acc.2022.06.006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Tada H, Nomura A, Ogura M, Ikewaki K, Ishigaki Y, Inagaki K, Tsukamoto K, Dobashi K, Nakamura K, Hori M, Matsuki K, Yamashita S, Yokoyama S, Kawashiri MA, Harada-Shiba M. Diagnosis and Management of Sitosterolemia 2021. J Atheroscler Thromb, 2021; 28: 791-801","DOI":"10.5551\/jat.RV17052"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Higashiyama A, Kohsaka S, Fujiyoshi A. Primary Prevention of Coronary and Other Cardiovascular Diseases: A Focused Review. J Atheroscler Thromb, 2024; 31: 1113-1128","DOI":"10.5551\/jat.RV22019"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A, Yanai H. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb, 2024; 31: 641-853","DOI":"10.5551\/jat.GL2022"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, White J, Tershakovec A, Braunwald E. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol, 2018; 6: 934-943","DOI":"10.1016\/S2213-8587(18)30290-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, Bruckert E, Freiberger T, Gaudet D, Harada-Shiba M, Hudgins LC, Kayikcioglu M, Masana L, Parhofer KG, Roeters van Lennep JE, Santos RD, Stroes ESG, Watts GF, Wiegman A, Stock JK, Tokg\u00f6zo\u011flu LS, Catapano AL, Ray KK. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J, 2023; 44: 2277-2291","DOI":"10.1093\/eurheartj\/ehad197"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Byty\u00e7i I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, Thompson PD, Mazidi M, Rysz J, Pella D, Reiner \u017d, Toth PP, Banach M. Prevalence of statin intolerance: a meta-analysis. Eur Heart J, 2022; 43: 3213-3223","DOI":"10.1093\/eurheartj\/ehac015"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. J Clin Lipidol, 2016; 10: 739-747","DOI":"10.1016\/j.jacl.2016.05.002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstr\u00f6m B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gr\u00f6nhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, 2011; 377: 2181-2192","DOI":"10.1016\/S0140-6736(11)60739-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, Urabe T, Uchida Y, Hayashi M, Yokota N, Nishida H, Otonari T, Arai T, Sakuma I, Sakabe K, Yamamoto M, Kobayashi T, Oikawa S, Yamashita S, Rakugi H, Imai T, Tanaka S, Ohashi Y, Kuwabara M, Ito H. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. Circulation, 2019; 140: 992-1003","DOI":"10.1161\/CIRCULATIONAHA.118.039415"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Abdul-Rahman T, Bukhari SMA, Herrera EC, Awuah WA, Lawrence J, de Andrade H, Patel N, Shah R, Shaikh R, Capriles CAA, Ulusan S, Ahmad S, Corriero AC, Mares AC, Goel A, Hajra A, Bandyopadhyay D, Gupta R. Lipid Lowering Therapy: An Era Beyond Statins. Curr Probl Cardiol, 2022; 47: 101342","DOI":"10.1016\/j.cpcardiol.2022.101342"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Kuder JF, Murphy SA, Walsh E, Wang H, Blaha V, Budaj A, Cornel JH, Goudev A, Kiss RG, Lorenzatti AJ, Parkhomenko A, Cyrille M, Paiva da Silva Lima G, Ohman EM, Giugliano RP, Sabatine MS; VESALIUS-CV Investigators. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med, 2026; 394: 117-127","DOI":"10.1056\/NEJMoa2514428"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Barkas F, Ray K. An update on inclisiran for the treatment of elevated LDL cholesterol. Expert Opin Pharmacother, 2024; 25: 349-358","DOI":"10.1080\/14656566.2024.2337253"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Yamashita S, Kiyosue A, Fujita H, Yokota D, Nakamura Y, Yasuda S. Efficacy and Safety of Bempedoic Acid in Japanese Patients With Hypercholesterolemia- A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (the CLEAR-J Trial). Circ J, 2025; 89: 1256-1265","DOI":"10.1253\/circj.CJ-25-0089"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med, 2023; 388: 1353-1364","DOI":"10.1056\/NEJMoa2215024"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Reijman MD, Kusters DM, Groothoff JW, Arbeiter K, Dann EJ, de Boer LM, de Ferranti SD, Gallo A, Greber-Platzer S, Hartz J, Hudgins LC, Ibarretxe D, Kayikcioglu M, Klingel R, Kolovou GD, Oh J, Planken RN, Stefanutti C, Taylan C, Wiegman A, Schmitt CP. Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN. Atherosclerosis, 2024; 392: 117525","DOI":"10.1016\/j.atherosclerosis.2024.117525"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Schettler VJJ. Lipoprotein apheresis: Current overview and future outlook in clinical practice. Transfus Apher Sci, 2025; 64: 104209","DOI":"10.1016\/j.transci.2025.104209"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Muso E, Kakita H, Suzuki H, Tsukamoto T. Updated evidence of beneficial effect of LDL apheresis for refractory nephrotic syndrome due to a variety of causative diseases for nationwide and global approval. Ther Apher Dial, 2023; 27: 987-999","DOI":"10.1111\/1744-9987.14056"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Kameyama N, Maruyama C, Kitagawa F, Nishii K, Uenomachi K, Katayama Y, Koga H, Chikamoto N, Kuwata Y, Torigoe J, Arimoto M, Tokumaru T, Ikewaki K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, Harada-Shiba M. Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia. J Atheroscler Thromb, 2019; 26: 72-83","DOI":"10.5551\/jat.44107"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Harada-Shiba M, Haruna S, Kogawa N. Real-world safety and efficacy of lomitapide in homozygous familial hypercholesterolemia: interim report of special-use survey in Japan. Future Cardiol, 2024; 20: 67-80","DOI":"10.2217\/fca-2023-0136"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, Bruckert E, Freiberger T, Gaudet D, Harada-Shiba M, Hudgins LC, Kayikcioglu M, Masana L, Parhofer KG, Roeters van Lennep JE, Santos RD, Stroes ESG, Watts GF, Wiegman A, Stock JK, Tokg\u00f6zo\u011flu LS, Catapano AL, Ray KK. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J, 2023; 44: 2277-2291","DOI":"10.1093\/eurheartj\/ehad197"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Fukami H, Oike Y. ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis. J Atheroscler Thromb, 2025; 32: 1071-1078","DOI":"10.5551\/jat.RV22038"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, Khilla N, Hamlin R, Pordy R, Dong Y, Son V, Gaudet D. Evinacumab in Patients with Refractory Hypercholesterolemia. N Engl J Med, 2020; 383: 2307-2319","DOI":"10.1056\/NEJMoa2031049"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Rosenson RS, Brinton EA, Gaudet D, Raal FJ, Baker-Smith C, Moriarty PM, Greber-Platzer S, Bergeron J, McCrindle BW, Waldron A, Ali S, George RT, Pordy R, Zhao XQ, Wiegman A. Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia. Atherosclerosis, 2025; 413: 120627","DOI":"10.1016\/j.atherosclerosis.2025.120627"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, Kimura K, Ozaki Y, Murohara T, Ueshima K, Kuwabara Y, Tanaka-Mizuno S, Yanagisawa N, Sato T, Daida H; RESPECT-EPA Investigators. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation, 2024; 150: 425-434","DOI":"10.1161\/CIRCULATIONAHA.123.065520"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Basak A. Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects. Biomolecules, 2025; 15: 468","DOI":"10.3390\/biom15040468"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Garwood CL, Cabral KP, Brown R, Dixon DL. Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review. Pharmacotherapy, 2025; 45: 54-65","DOI":"10.1002\/phar.4635"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Inazu A. Cholesteryl Ester Transfer Protein Deficiency and Hyperalphalipoproteinemia. J Atheroscler Thromb, 2025; 32: 911-923","DOI":"10.5551\/jat.RV22037"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Tada H, Furukawa A, Kojima N, Usui S, Sakata K, Kawashiri MA, Takamura M. Protein-truncating variants of the cholesteryl ester transfer protein gene and risk for coronary artery disease among patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 2025; 408: 120417","DOI":"10.1016\/j.atherosclerosis.2025.120417"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Nicholls SJ, Nelson AJ, Ray KK, Ballantyne CM, Ditmarsch M, Kling D, Hsieh A, Szarek M, Kastelein JJ, Davidson MH. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol, 2025; 86: 1046-1056","DOI":"10.1016\/j.jacc.2025.07.056"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Kronenberg F, Bedlington N, Ademi Z, Geant\u0103 M, Silberzahn T, Rijken M, Kaal A, Harada-Shiba M, Chen Z, Thanassoulis G, Eliasen B, Eisel\u00e9 JL, Wiegman A, Ballantyne CM, Broome E, Calabr\u00f2 M, Corral P, Dol A, Donato LJ, Evans E, Funabashi S, Gouni-Berthold I, Ibarluzea IG, Johnson N, Lane J, Mora S, Nordestgaard BG, Pe\u0107in I, Kaal-Poppelaars R, Langlois MR, Ray KK, Rodenbach A, Santos RD, Stroes ESG, Tada H, Vrabl\u00edk M, Winokur M, Yoshida M, Nicholls SJ, Daccord M. The Brussels International Declaration on Lipoprotein(a) Testing and Management. Atherosclerosis, 2025; 406: 119218","DOI":"10.1016\/j.atherosclerosis.2025.119218"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Tada H, Yamagami K, Sakata K, Usui S, Kawashiri MA, Takamura M. Healthy lifestyle, lipoprotein (a) levels and the risk of coronary artery disease. Eur J Clin Invest, 2024; 54: e14093","DOI":"10.1111\/eci.14093"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Formisano P, Vianello E, Dozio E, Tacchini L, Romani L, Frati L, Curcio F, Bellet MM, Corsi-Romanelli MM. Lp(a) in the Horizon of Diagnostics and Therapy. Int J Mol Sci, 2025; 27: 290","DOI":"10.3390\/ijms27010290"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Miida T, Hirayama S, Fukushima Y, Hori A, Ito S, Hinata M, Wakita M, Tabata H, Tamura Y, Watada H, Kawamori R, Vesper HW, Cobbaert CM. Harmonization of Lipoprotein(a) Immunoassays Using A Serum Panel Value Assigned with The IFCC-Endorsed Mass Spectrometry-Based Reference Measurement Procedure as A First Step Towards Apolipoprotein Standardization. J Atheroscler Thromb, 2025; 32: 580-595","DOI":"10.5551\/jat.65238"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Hermel M, Chiou A, Minhas AMK, Inam M, Waldman CE, Youngblood E, Mehta S, Slipczuk L, Sheikh S, Meloche C, Khoja A, Virani SS. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions. Curr Atheroscler Rep, 2024; 26: 119-131","DOI":"10.1007\/s11883-024-01193-8"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/9\/33_RV22052\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:52:23Z","timestamp":1788583943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/9\/33_RV22052\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv22052","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"RV22052"}}